SCHEMBL944345

SCHEMBL944345

NC(=O)c1ccnc(Oc2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.58
MAPK10 P53779 1/20 0.58
PARP10 Q53GL7 3/20 0.54
LOXL2 Q9Y4K0 10/20 0.54
LOX P28300 7/20 0.53
F2 P00734 2/20 0.51
F10 P00742 2/20 0.51
TNKS O95271 1/20 0.49
PARP15 Q460N3 1/20 0.49
PARP14 Q460N5 1/20 0.49
TNKS2 Q9H2K2 1/20 0.49
PARP2 Q9UGN5 1/20 0.49
OPRK1 P41145 2/20 0.47
KCNH2 Q12809 1/20 0.47
FFAR1 O14842 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
OPRM1 P35372 1/20 0.45
OPRD1 P41143 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL238350 0.87 LOXL2 (0.59) MAPK8MAPK10LOXL2LOXF2
SCHEMBL27569210 0.83 OPRK1 (0.49) MAPK8MAPK10PARP10LOXL2LOX
SCHEMBL28439623 0.81 KDM4E (0.55) MAPK8MAPK10LOXL2LOXNPC1
Benzamide SCHEMBL27324266 0.81 PARP10 (0.59) MAPK8MAPK10PARP10LOXL2F2
SCHEMBL27569211 0.79 OPRM1 (0.47) MAPK8MAPK10LOXL2LOXOPRK1
SCHEMBL3702576 0.79 OPRM1 (0.72) OPRK1KCNH2OPRM1OPRD1
SCHEMBL7635169 0.79 LOXL2 (0.67) LOXL2LOXNPC1RAB9A
SCHEMBL1758360 0.79 PARP10 (0.57) PARP10TNKSPARP15PARP14TNKS2
SCHEMBL23189218 0.78 TNKS (0.58) MAPK8MAPK10PARP10LOXL2LOX
SCHEMBL445784 0.76 NNMT (0.56) PARP10LOXL2LOXPARP2OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009437-A1 CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-01-13 US claimed
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
US-9695162-B2 Sweet flavor modifier SENOMYX, INC. (US) 2017-07-04 US disclosed
US-20170029416-A1 SWEET FLAVOR MODIFIER SENOMYX, INC. 2017-02-02 US disclosed
US-20110009437-A1 CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-01-13 US disclosed
EP-0488474-B1 Herbicidal carboxamide derivatives BASF AG (DE) 2002-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 MAPK8 960/4885MAPK10 1375/4885PARP10 1592/4885
US-20110009437-A1 CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES GLS, GCKR, HK1 MAPK8 1493/4885MAPK10 2258/4885PARP10 3777/4885
US-20170029416-A1 SWEET FLAVOR MODIFIER TAS2R5, TAS2R10, TAS2R50 MAPK8 4455/4885MAPK10 3297/4885PARP10 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.